RxDoctor Payments Data

Marc Scheiner, MD

Clinical Cardiac Electrophysiology · East Brunswick, NJNPI 1245268077

Payments from drug & device makers

$2,620in general payments, 2019–2025

Across 234 payments — averaging $11.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kowa Pharmaceuticals America, Inc.$782
  • Novartis$439
  • Boston Scientific$389
  • E.r. Squibb & Sons, L.L.C.$188
  • Johnson & Johnson$160
  • Vivus LLC$104
  • plus $558 from 20 others

What the payments were for

  • Food & beverage$2,59899%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,620 in reported general payments places this provider in the 5th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

See all clinical cardiac electrophysiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$385,851
Medicare patients
968
Services billed
4,237

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban497$693,622
EntrestoSacubitril/Valsartan108$169,101
XareltoRivaroxaban104$147,072
MultaqDronedarone Hcl42$61,114
Repatha SureclickEvolocumab15$23,226
FarxigaDapagliflozin Propanediol14$19,241
Propafenone Hcl ErPropafenone Hcl32$9,994
Metoprolol Succinate434$8,000
Dabigatran EtexilateDabigatran Etexilate Mesylate17$7,710
Flecainide Acetate151$7,000
Pitavastatin Calcium13$5,784
Rosuvastatin Calcium265$4,627
Atorvastatin Calcium406$4,506
Amiodarone Hcl65$4,417
Diltiazem 24hr Er (Cd)Diltiazem Hcl97$3,848

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$44$693,622497 claims
NovartisEntresto$439$169,101108 claims
Johnson & JohnsonXarelto$160$147,072104 claims
Sanofi-aventis U.S. LLCMultaq$15$61,11442 claims
AstraZenecaFarxiga$26$19,24114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.

Other clinical cardiac electrophysiology in East Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →